Immune Design Corp. (NASDAQ:IMDZ) major shareholder Leo Guthart acquired 60,000 shares of the firm’s stock in a transaction dated Tuesday, October 24th. The stock was purchased at an average cost of $4.65 per share, with a total value of $279,000.00. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Leo Guthart also recently made the following trade(s):

  • On Thursday, October 19th, Leo Guthart acquired 10,000 shares of Immune Design Corp. stock. The stock was purchased at an average cost of $6.09 per share, with a total value of $60,900.00.
  • On Monday, September 18th, Leo Guthart acquired 10,000 shares of Immune Design Corp. stock. The stock was purchased at an average cost of $9.70 per share, with a total value of $97,000.00.

Shares of Immune Design Corp. (NASDAQ:IMDZ) traded down 16.35% during mid-day trading on Tuesday, hitting $4.35. 2,808,784 shares of the company traded hands. The stock’s market capitalization is $111.44 million. The firm has a 50-day moving average of $9.81 and a 200-day moving average of $8.59. Immune Design Corp. has a one year low of $4.00 and a one year high of $13.05.

Immune Design Corp. (NASDAQ:IMDZ) last posted its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.54) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.65) by $0.11. The company had revenue of $0.73 million during the quarter, compared to analyst estimates of $1.50 million. Immune Design Corp. had a negative net margin of 324.33% and a negative return on equity of 59.14%. On average, equities analysts predict that Immune Design Corp. will post ($2.29) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Immune Design Corp. (IMDZ) Major Shareholder Leo Guthart Buys 60,000 Shares” was first published by American Banking News and is the sole property of of American Banking News. If you are reading this report on another domain, it was copied illegally and reposted in violation of US and international copyright laws. The correct version of this report can be accessed at https://www.americanbankingnews.com/2017/10/24/immune-design-corp-imdz-major-shareholder-leo-guthart-buys-60000-shares.html.

A number of research analysts have recently commented on IMDZ shares. Wells Fargo & Company downgraded shares of Immune Design Corp. from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $29.00 to $10.00 in a research report on Tuesday, October 17th. Zacks Investment Research raised shares of Immune Design Corp. from a “hold” rating to a “buy” rating and set a $11.00 price objective for the company in a research report on Tuesday, July 18th. ValuEngine downgraded shares of Immune Design Corp. from a “sell” rating to a “strong sell” rating in a research report on Saturday. Jefferies Group LLC reissued a “buy” rating and issued a $18.00 price objective on shares of Immune Design Corp. in a research report on Wednesday, June 28th. Finally, Royal Bank Of Canada started coverage on shares of Immune Design Corp. in a research report on Thursday, September 14th. They issued an “outperform” rating and a $20.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $14.75.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Victory Capital Management Inc. grew its position in Immune Design Corp. by 2.1% during the second quarter. Victory Capital Management Inc. now owns 1,977,564 shares of the biotechnology company’s stock valued at $19,281,000 after buying an additional 40,010 shares during the period. Franklin Resources Inc. grew its position in Immune Design Corp. by 2.7% during the second quarter. Franklin Resources Inc. now owns 760,253 shares of the biotechnology company’s stock valued at $7,412,000 after buying an additional 20,000 shares during the period. JPMorgan Chase & Co. grew its position in Immune Design Corp. by 118.7% during the second quarter. JPMorgan Chase & Co. now owns 530,702 shares of the biotechnology company’s stock valued at $5,175,000 after buying an additional 288,009 shares during the period. Vanguard Group Inc. grew its position in Immune Design Corp. by 37.9% during the second quarter. Vanguard Group Inc. now owns 524,999 shares of the biotechnology company’s stock valued at $5,118,000 after buying an additional 144,408 shares during the period. Finally, FMR LLC grew its position in Immune Design Corp. by 0.4% during the first quarter. FMR LLC now owns 445,152 shares of the biotechnology company’s stock valued at $3,027,000 after buying an additional 1,699 shares during the period. Institutional investors own 51.47% of the company’s stock.

Immune Design Corp. Company Profile

Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.

Insider Buying and Selling by Quarter for Immune Design Corp. (NASDAQ:IMDZ)

Receive News & Ratings for Immune Design Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design Corp. and related companies with MarketBeat.com's FREE daily email newsletter.